There are currently 979 clinical trials in San Antonio, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Health Science Center at San Antonio, GSK Investigational Site, Pfizer Investigational Site and Methodist Children's Hospital of South Texas. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Non-Surgical Management of Knee Osteoarthritis in the Military Health System (MHS)
NCT03747393
Recruiting
This study will compare two different treatment approaches for the management of knee osteoarthritis (OA). All subjects will receive a standardized approach consistent with the core set of recommendation from the Department of Defense (DoD) and Veterans Administration (VA) Clinical Practice Guidelines for Non-Surgical Management of Knee Osteoarthritis. Follow-up will occur over a 1 year period.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
07/30/2024
Locations: Brooke Army Medical Center, San Antonio, Texas +1 locations
Conditions: Knee Osteoarthritis
Register for Updates
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
NCT00920972
Recruiting
The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells. It is also to determine major toxicities from these conditioning regimens, within the first 100 days after transplantation.
Gender:
ALL
Ages:
20 years and below
Trial Updated:
07/19/2024
Locations: Texas Transplant Institute, San Antonio, Texas
Conditions: Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies, Non-malignant Disorders
Register for Updates
Echography Study_Anthropometric Measurements
NCT06279689
Recruiting
This is a multi-center, exploratory, estimation study in both adult and pediatric populations. There is no investigational product injection during this study The exploratory objective of this study is to evaluate the anatomical characteristics of both anterolateral thighs in healthy adult and healthy pediatric populations (2 to 17 years old) by ultrasound scan before and while applying a force similar to the ZENEO® triggering force. In the healthy adult population, anatomical characteristics o... Read More
Gender:
ALL
Ages:
Between 2 years and 70 years
Trial Updated:
07/19/2024
Locations: Clinical Trials of Texas, LLC dba Flourish Research, San Antonio, Texas
Conditions: Healthy Subjects
Register for Updates
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT04198766
Recruiting
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2024
Locations: NEXT Oncology, San Antonio, Texas
Conditions: Solid Tumor, Non-Small Cell Lung Cancer, Melanoma, Head and Neck Cancer, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma
Register for Updates
A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment
NCT06352528
Recruiting
The purpose of this study is to assess the drug levels of a single oral dose of repotrectinib in participants with moderate and severe HI, and in healthy matched control participants with normal hepatic function.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/10/2024
Locations: Local Institution - 0004, San Antonio, Texas +1 locations
Conditions: Hepatic Impairment, Healthy Volunteers
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: University of Texas Health Science Center at San Antonio, San Antonio, Texas
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
External Lumbar Drainage to Reduce ICP in Severe TBI: a Phase 1 Clinical Trial
NCT05889650
Recruiting
The goal of this phase 1 randomized controlled safety and feasibility clinical trial are to determine the safety of external lumbar drainage (ELD) in select patients with severe Traumatic Brain Injury (TBI). The main questions it aims to answer are (i) if ELD is feasible and (ii) safe to perform in severe TBI patients who have radiological evidence of patent basal cisterns and midline shift \<5mm without increasing the risk of neurological worsening or cerebral herniation. All participants will... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/24/2024
Locations: University of Texas, San Antonio, Texas
Conditions: Severe Traumatic Brain Injury, Intracranial Hypertension
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: GSK Investigational Site, San Antonio, Texas
Conditions: Neoplasms
Register for Updates
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
NCT05483868
Recruiting
The main objectives of this study are to determine the feasibility and safety of AU-011 treatment of bladder cancer utilizing intratumoral injection with or without intramural injection and with or without laser application.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: The University of Texas San Antonio, San Antonio, Texas +1 locations
Conditions: Non-muscle-invasive Bladder Cancer, Muscle-Invasive Bladder Carcinoma
Register for Updates
A Research Study on Etavopivat in Participants With and Without Liver Disease
NCT06336018
Recruiting
The study investigates an investigational drug called etavopivat in participants with hepatic impairments and participants with normal hepatic function (matched controls). During the study, all participants will be given a single oral dose of etavopivat. All participants will take the etavopivat orally together with water. After dosing, the study will last for 7 to 9 days.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Amer. Rrsch Corp-TX Liver Inst, San Antonio, Texas
Conditions: Liver Diseases
Register for Updates
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
NCT04092673
Recruiting
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of Zotatifin (eFT226) in subjects with selected advanced solid tumor malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: New Experimental Therapeutics of San Antonio - NEXT Oncology, San Antonio, Texas
Conditions: Solid Tumor, Adult
Register for Updates
KIOS Mobile App Evaluation
NCT06212557
Recruiting
Evaluation of a mobile medical app (KIOS) vs. treatment as usual for the treatment of opioid use disorder (OUD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: University of Texas Health Science Center - Department of Psychiatry, San Antonio, Texas
Conditions: Opioid Use Disorder
Register for Updates